A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference7 articles.
1. Basal cell carcinomas: attack of the hedgehog;Epstein;Nat Rev Cancer,2008
2. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma;Macha;Cancer Manage Res,2013
3. Efficacy and safety of vismodegib in advanced basal-cell carcinoma;Sekulic;N Engl J Med,2012
4. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors;LoRusso;Clin Cancer Res,2011
5. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission;Kaye;Clin Cancer Res,2012
Cited by 69 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug-induced scarring and permanent alopecia;JAAD Reviews;2024-09
2. Reply to M. Boileau et al;Journal of Clinical Oncology;2024-08-02
3. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review;PLOS ONE;2024-04-30
4. Effect of low-intensity focused ultrasound therapy on postpartum uterine involution in puerperal women: A randomized controlled trial;PLOS ONE;2024-04-30
5. The top 100 most cited articles in the treatment of basal cell carcinoma over the last decade: A bibliometric analysis and review;Medicine;2024-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3